Ascendis Pharma AS (NASDAQ:ASND) was upgraded by stock analysts at TheStreet from a “sell” rating to a “hold” rating in a research report issued on Tuesday.
ASND has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Ascendis Pharma AS from a “hold” rating to a “sell” rating in a research note on Tuesday, May 24th. Leerink Swann reissued a “buy” rating on shares of Ascendis Pharma AS in a report on Friday, September 2nd.
Shares of Ascendis Pharma AS (NASDAQ:ASND) traded down 0.10% on Tuesday, reaching $19.71. 29,298 shares of the company were exchanged. The company’s market cap is $495.27 million. Ascendis Pharma AS has a 12 month low of $11.92 and a 12 month high of $20.54. The company’s 50-day moving average price is $16.34 and its 200 day moving average price is $15.89.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/10/ascendis-pharma-as-asnd-upgraded-at-thestreet.html
Ascendis Pharma AS (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, August 31st. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.10. On average, equities research analysts expect that Ascendis Pharma AS will post ($3.17) EPS for the current year.
About Ascendis Pharma AS
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma AS Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ascendis Pharma AS and related companies with MarketBeat.com’s FREE daily email newsletter.